Claims

1. A nucleic acid sequence that codes a gene product or a portion thereof, comprising

a) a nucleic acid sequence, selected from the group Seq. ID Nos. 1-126 and Seq. ID Nos. 531-552, 554, and 555,

b) an allelic variation of the nucleic acid sequences named under a)

or

c) a nucleic acid sequence that is complementary to the nucleic acid sequences named under a) or b).

2. A nucleic acid sequence according to one of the sequences Seq. ID Nos. 1-126 and Seq. ID Nos. 531-552, 554, and 555 or a complementary or allelic variant thereof.

3. Nucleic acid sequences Seq. ID No. 1 to Seq. ID No. 141 and Seq. ID Nos. 531-552, 554, and 555, characterized in that they are expressed elevated in uterus tumor tissue.

4. BAC, PAC and cosmid clones containing functional genes and their chromosomal localization according to sequences Seq. ID No. 1 to Seq. ID No. 141 and Seq. ID Nos. 531-552, 554, and 555 for use as vehicles for gene transfer.

5. A nucleic acid sequence according to ~~claims 1 to 4~~ claim 3, wherein it has 90% homology to a human nucleic acid sequence.

6. A nucleic acid sequence according to ~~claims 1 to 4~~ claim 3, wherein it has 95% homology to a human nucleic acid sequence.

sub A1 7. A nucleic acid sequence comprising a portion of the nucleic acid sequences named in claims 1 to 6, in such a sufficient amount that they hybridize with the sequences according to claims 1 to 6.

8. A nucleic acid sequence according to claim 3 ~~claims 1 to 7~~, wherein the size of the fragment has a length of at least 50 to 4500 bp.

9. A nucleic acid sequence according to claim 3 ~~claims 1 to 7~~, wherein the size of the fragment has a length of at least 50 to 4000 bp.

10. A nucleic acid sequence according to one of claim 3 ~~claims 1 to 9~~, which codes at least one partial sequence of a bioactive polypeptide.

11. An expression cassette, comprising a nucleic acid fragment or a sequence according to one of claim 3 ~~claims 1 to 9~~, together with at least one control or regulatory sequence.

12. An expression cassette, comprising a nucleic acid fragment or a sequence according to claim 11, in which the control or regulatory sequence is a suitable promoter.

13. An expression cassette according to one of claim 11 ~~claims 11 and 12~~, wherein the DNA sequences located on the cassette code a fusion protein, which comprises a known protein and a bioactive polypeptide fragment.

14. Use of nucleic acid sequences according to claim 3 ~~claims 1 to 10~~ for producing full-length genes.

15. A DNA fragment, comprising a gene, that can be obtained from the use according to claim 14.

16. Host cell, containing as the heterologous part of its expressible genetic information a nucleic acid fragment according to one of ~~claims 1 to 10.~~ claim 3

17. Host cell according to claim 16, wherein it is a prokaryotic or eukaryotic cell system.

18. Host cell according to one of ~~claims 16 or 17~~, claim 16 wherein the prokaryotic cell system is E. coli, and the eukaryotic cell system is an animal, human or yeast cell system.

19. A process for producing a polypeptide or a fragment, wherein the host cells according to ~~claims 16 to 18~~ claim 16 are cultivated.

20. An antibody that is directed against a polypeptide or a fragment that is coded by the nucleic acids of sequences Seq. ID No. 1 to Seq. ID No. 141 and Seq. ID Nos. 531-552, 554, and 555, which can be obtained according to claim 19.

21. An antibody according to claim 20, wherein it is monoclonal.

22. An antibody according to claim 20, wherein it is a phage display antibody.

23. Polypeptide partial sequences according to sequences Seq. ID Nos. Seq. 142-528 and Seq. ID Nos. Seq. 561-575, 577-625, and 630-635.

24. Polypeptide partial sequences according to claim 23, with at least 80% homology to these sequences.

25. A polypeptide that is known from a phage display and that can bind to the polypeptide partial sequences according to claim 23.

26. Polypeptide partial sequences according to claim 23, with at least 90% homology to these sequences.

27. Use of polypeptide partial sequences according to sequences Seq. ID Nos. 142-528 and Seq. ID Nos. Seq. 561-575, 577-625, and 630-635 as tools for finding active ingredients against uterus tumors.

28. Use of nucleic acid sequences according to sequences Seq. ID No. 1 to Seq. ID No. 141 and Seq. ID Nos. 531-552, 554, and 555 claim 23 for expression of polypeptides that can be used as tools for finding active ingredients against the endometrial tumor.

29. Use of nucleic acid sequences Seq. ID No. 1 to Seq. ID No. 141 and Seq. ID Nos. 531-552, 554, and 555 claim 23 in sense or antisense form.

30. Use of polypeptide partial sequences Seq. ID Nos. 142-528 and Seq. ID Nos. Seq. 561-575, 577-625, and 630-635 as pharmaceutical agents in gene therapy for treatment of the endometrial tumor.

31. Use of polypeptide partial sequences Seq. ID Nos. 142-528 and Seq. ID Nos. Seq. 561-575, 577-625, and 630-635 for the production of a pharmaceutical agent for treatment of the endometrial tumor.

32. Pharmaceutical agent, containing at least one polypeptide partial sequence Seq. ID Nos. 142-528 and Seq. ID Nos. Seq. 561-575, 577-625, and 630-635.

33. A nucleic acid sequence according to claim 3 ~~claims 1 to 10~~, wherein it is a genomic sequence.

34. A nucleic acid sequence according to [claim 3] ~~claims 1 to 10,~~ wherein it is an mRNA sequence.

35. Genomic genes, their promoters, enhancers, silencers, exon structure, intron structure and their splice variants, that can be obtained from cDNAs of sequences Seq. ID No. 1 to Seq. ID No. 141 and Seq. ID Nos. 531-552, 554, and 555 [claim 8].

36. Use of the genomic genes according to claim 35, together with suitable regulatory elements.

37. Use according to claim 36, wherein the regulatory element is a suitable promoter and/or enhancer.

38. A nucleic acid sequence according to [claim 3] ~~claims 1 to 7,~~ wherein the size of the fragment has a length of at least 300 to 3500 bp.